ERYTECH Provides Business Update and Reports Financial Highlights for Third Quarter 2016 Post author:admERY Post published:November 3, 2016 Post category:Newsroom ERYTECH today provided a business update and reported its financial results for the quarter ended September 30, 2016. You Might Also Like ERYTECH receives Orphan Drug Designation by the FDA for eryaspase in Acute Myeloid Leukemia April 2, 2014 ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2020 September 21, 2020 ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI Annual Meeting January 18, 2019
ERYTECH receives Orphan Drug Designation by the FDA for eryaspase in Acute Myeloid Leukemia April 2, 2014
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2020 September 21, 2020
ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI Annual Meeting January 18, 2019
